Chung Thomas Kam-Man, Leung Thomas Wai-Tong, Chung Cheuk-Hei, Leung Howard Ho-Wai, Lau Wan Yee
Department of Surgery, Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong, China.
Comprehensive Oncology Center, Hong Kong Sanatorium of Hospital, 2 Village Road, Happy Valley, Hong Kong, China.
Int J Surg Case Rep. 2022 Jan;90:106679. doi: 10.1016/j.ijscr.2021.106679. Epub 2021 Dec 28.
Hepatocellular carcinoma (HCC) is a common disease. Many patients at the time of diagnosis of HCC are in advanced stages and cannot benefit from curative treatment. Palliative treatments remain the only treatment option. Advances in palliative treatment can occasionally downstage HCC and induce enough liver hypertrophy to allow salvage hepatectomy to be performed on patients with initially unresectable HCC. We herein present a patient who underwent salvage hepatectomy after successful Ablative-Transarterial Radioembolization (A-TARE) with complete histopathologic response in the resected liver specimen.
A 67-year old obese patient presented with a 9.7 cm HCC at liver segment 8, with local tumour extension to involve segments 4,5 and 7. Initial workup suggested the tumour to be unresectable. A-TARE with yttrium-90 microspheres was given. Further workup 4 months after A-TARE showed the tumour to be downstaged with adequate hypertrophy of future liver remnant. Salvage hepatectomy became possible and the patient underwent salvage trisectionectomy 5 months after A-TARE. He recovered uneventfully from the operation. Histopathological examination of the resected liver specimen showed no viable tumour cells inside a fibrous mass which corresponded to the radiologic residual tumour.
Salvage hepatectomy should be offered to patients after tumour downstaging with A-TARE as viable malignant cells are likely to persist. Complete response with no viable tumour cells in the resected liver specimen, to our knowledge, has never been reported in literature.
A-TARE was able to induce complete histopathological response in a patient who initially presented with a large and unresectable HCC mass.
肝细胞癌(HCC)是一种常见疾病。许多HCC患者在确诊时已处于晚期,无法从根治性治疗中获益。姑息性治疗仍然是唯一的治疗选择。姑息性治疗的进展偶尔可使HCC降期,并诱导足够的肝脏肥大,从而使最初无法切除的HCC患者能够接受挽救性肝切除术。我们在此报告一例患者,其在成功进行消融 - 经动脉放射性栓塞术(A-TARE)后出现完全组织病理学反应,随后接受了挽救性肝切除术,切除的肝脏标本中未见存活肿瘤细胞。
一名67岁肥胖患者,肝段8出现一个9.7厘米的HCC,局部肿瘤侵犯至肝段4、5和7。初步检查提示肿瘤无法切除。给予钇 - 90微球进行A-TARE治疗。A-TARE治疗4个月后的进一步检查显示肿瘤降期,未来肝残余有足够的肥大。挽救性肝切除术成为可能,该患者在A-TARE治疗5个月后接受了挽救性三段切除术。他术后恢复顺利。切除的肝脏标本的组织病理学检查显示,在与放射学残留肿瘤相对应的纤维肿块内未见存活肿瘤细胞。
在A-TARE使肿瘤降期后,应向患者提供挽救性肝切除术,因为可能仍有存活的恶性细胞。据我们所知,在切除的肝脏标本中出现无存活肿瘤细胞的完全缓解情况在文献中从未报道过。
A-TARE能够在一名最初表现为巨大且无法切除的HCC肿块的患者中诱导出完全的组织病理学反应。